We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ATNM market cap is 37.12M. The company's latest EPS is USD -1.5649 and P/E is -0.74.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 81k | 0 | 0 | 0 |
| Operating Income | -14.35M | -10.34M | -9.6M | -12.42M | -12.6M |
| Net Income | -13.28M | -9.32M | -8.67M | -11.35M | -11.57M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 1.14M | 1.03M | 81k |
| Operating Income | -22.07M | -22.39M | -24.96M | -34.1M | -51.92M |
| Net Income | -21.9M | -22.22M | -24.77M | -33.02M | -48.82M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 88.94M | 81.45M | 88.35M | 89.86M | 82.11M |
| Total Liabilities | 45.36M | 45.07M | 44.5M | 46.03M | 43.91M |
| Total Equity | 43.58M | 36.38M | 43.86M | 43.84M | 38.21M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 11.67M | 66.4M | 80.39M | 114.19M | 81.45M |
| Total Liabilities | 6.03M | 5.08M | 6.84M | 47.71M | 45.07M |
| Total Equity | 5.64M | 61.32M | 73.55M | 66.48M | 36.38M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -39.85M | -47.34M | -7.37M | -15.35M | -27.32M |
| Investing | -153k | -153k | -11k | -11k | -11k |
| Financing | 13.68M | 14.87M | 14.77M | 24.72M | 29.32M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.46M | -21.62M | -20.87M | 8.64M | -47.34M |
| Investing | -64k | -253k | -133k | -366k | -153k |
| Financing | 17.11M | 76.18M | 35.22M | 23.11M | 14.87M |
| Market Cap | 37.12M |
| Price to Earnings Ratio | -0.74 |
| Price to Sales Ratio | 446.15 |
| Price to Cash Ratio | 0.47 |
| Price to Book Ratio | 0.99 |
| Dividend Yield | - |
| Shares Outstanding | 31.2M |
| Average Volume (1 week) | 139.63k |
| Average Volume (1 Month) | 197.88k |
| 52 Week Change | -78.52% |
| 52 Week High | 10.24 |
| 52 Week Low | 1.10 |
| Spread (Intraday) | 0.05 (4.17%) |
| Company Name | Actinium Pharmaceuticals Inc |
| Address |
108 w. 13th street suite 100 wilmington, delaware 19801 |
| Website | https://www.actiniumpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
